- Policy
- The benefit of 7 α-GPC products will be suspended
- by Lee, Hye-Kyung Oct 19, 2021 08:53pm
- Benefits for seven items that have been canceled for not participating in the clinical re-evaluation of the brain function improvement drug Choline alfoscerate will be suspended from the 21st. The MOHW announced on the 18th that it has decided to suspend health insurance benefits for drugs that have been canceled for product licenses due to c
- Policy
- Korea United Pharm's Galvusmet generic is the first approved
- by Lee, Tak-Sun Oct 19, 2021 06:00am
- Korea United Pharm received approval for the first generic of Novartis’s DPP-4 inhibitor, ‘Galvusmet (vildagliptin/metformin hydrochloride),’ an antidiabetic treatment. With the approval, the company will likely be competing with Hanmi Pharmaceutical next year, which marked the start of Galvusmet latecomers with a salt-modified drug i
- Policy
- Keytruda·Tagrisso is in the process of expanding benefits
- by Lee, Hye-Kyung Oct 18, 2021 05:54am
- There was an opinion calling for expediting the expansion of the benefit standard for tumor-agnostic therapy. Independent lawmaker Lee Yong-ho said in a parliamentary audit of the National Assembly's Health and Welfare Committee on the 15th, "Benefits of Keytruda & Tagrisso have not expanded and are causing pain to patients," adding, "Ke
- Policy
- “Impartiality of reimbursement review system undermined"
- by Lee, Jeong-Hwan Oct 18, 2021 05:54am
- The principal investigator of the clinical trial of lung cancer drug B participated in lung cancer A drug’s reimbursement assessment meeting. Isn’t this a conflict of interest and cause for the member’s exclusion from the committee?” (People Power Party Jung-sook Suh) “There are operational regulations set for the Cancer Disease Delib
- Policy
- Introduction of CDF for Zolgensma was proposed
- by Lee, Hye-Kyung Oct 18, 2021 05:54am
- When the National Assembly proposed the introduction of the Cancer Drugs Fund (CDF) for Zolgensma, the NHIS accepted the beginning of the discussion. Rep. Kim Sung-joo of the Democratic Party of Korea said in a parliamentary audit of the National Assembly's Health and Welfare Committee on the 15th, "There was a story of a new drug worth 2.
- Policy
- The HIRA also decided to disclose the results of Kymriah
- by Lee, Hye-Kyung Oct 15, 2021 05:58am
- The HIRA has decided to disclose the results of the drug benefit assessment. Although the entire evaluation process required by citizens, patient organizations, and the pharmaceutical industry is not disclosed in detail, it has decided to clearly disclose the establishment of benefit standards and appropriateness of benefits. The HIRA rele
- Policy
- Requests for confirmation of medical expenses, disclosed
- by Lee, Hye-Kyung Oct 15, 2021 05:57am
- After Avastin receiving the indication of macular degeneration, a patient who paid at his own expense requested confirmation of medical expenses, but the non-reimubrsed cases was justified. The HIRA released a case of requesting confirmation of non-reimbursed medical expenses in the third quarter. Patients can check the details of medical
- Policy
- A new drug preferential law will be promoted
- by Lee, Jeong-Hwan Oct 15, 2021 05:57am
- The MOHW announced that it will start enacting subordinate laws to substantially implement and secure the effectiveness of the "clause for preferential treatment of new domestic drugs" developed by innovative pharmaceutical companies under the Special Act on the Pharmaceutical Industry. The "upper limit price preferential treatment of drug
- Policy
- No need to extend the benefit period of Keytruda
- by Lee, Jeong-Hwan Oct 14, 2021 05:38am
- The MOHW said there is little need to extend the benefit period of Keytruda, an immuno-cancer drug, for patients who are effective in secondary treatment of non-small cell lung cancer by more than two years. This is because the clinical period of Keytruda was designed to be two years, and related societies such as the Korean Association fo
- Policy
- Poor ‘Benefit Adequacy Assessment' in controversy
- by Lee, Jeong-Hwan Oct 14, 2021 05:38am
- A bill to specify the basic definition of the Insurance Benefit Adequacy Assessment and stipulate the submission period for its data for assessment is being promoted. On the 13th, the National Assembly member Jong-Sik Heo announced that he had presented a bill for the partial amendment of the National Health Insurance Act that contained t
